Paul Efron - 31 Jul 2025 Form 3 Insider Report for Mallinckrodt plc

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 31 Jul 2025
Net transaction value: $0
SEC form: 3
Accepted by SEC: 04 Aug 2025, 20:43:47 UTC
Next SEC filing: 18 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Mark Tyndall, Attorney-in-Fact

Key filing fact

Paul Efron filed Form 3 for Mallinckrodt plc on 04 Aug 2025.

Key facts

This page summarizes Paul Efron's Form 3 filing for Mallinckrodt plc.
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 04 Aug 2025, 20:43.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002024711 Primary reporting owner

Efron Paul

Relationship: Director
Address: 675 MCDONNELL BLVD., HAZELWOOD
Signature: /s/ Mark Tyndall, Attorney-in-Fact
Signature date: 04 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 773
Date: 31 Jul 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. At the Merger Effective Time (as defined in the Transaction Agreement), each share of Endo common stock held by the reporting person immediately prior to the Merger Effective Time automatically converted into the right to receive approximately $1.31 in cash and 0.2575 ordinary shares of the Issuer without interest and subject to applicable withholding. The securities reported herein were acquired by the reporting person prior to the reporting person becoming a director of the Issuer.

Footnote F2

The reporting person became a director of the Issuer immediately following the effective time of the Business Combination.

SEC remarks

Exhibit 24 - Power of Attorney. This Form 3 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.